Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease.
Acute chest syndrome (ACS) is the leading cause of death in sickle cell disease. Severe ACS often develops in the course of a vaso-occlusive crisis (VOC), but currently there are no predictors for its development. Secretory phospholipase A(2) (sPLA(2)), a potent inflammatory mediator, is elevated in ACS, and previous work suggests that sPLA(2) predicts impending ACS. We prospectively evaluated sPLA(2) concentration during 21 admissions for VOC; 6 of these patients went on to develop ACS. Elevation of sPLA(2) was detected all 6 patients 24 to 48 hours before ACS was clinically diagnosed. Adding the requirement for fever raised the specificity of sPLA(2) to 87% while retaining 100% sensitivity. These data indicate that sPLA(2) can be useful in alerting the clinician to patients with impending ACS. In addition, sPLA(2) may be useful for instituting early therapies to prevent or reduce the clinical morbidity of ACS.
Styles
L A
LA
Department of Hematology/Oncology, Children's Hospital Oakland, CA 94609, USA. lstyles@landminds.com
Aarsman
A J
AJ
Vichinsky
E P
EP
Kuypers
F A
FA
D000208:Acute Disease; D000755:Anemia, Sickle Cell / Q000097:blood* / Q000150:complications* / Q000401:mortality; D015415:Biomarkers / Q000097:blood; D002637:Chest Pain / Q000175:diagnosis* / Q000209:etiology*; D003937:Diagnosis, Differential; D054501:Group II Phospholipases A2; D006801:Humans; D010741:Phospholipases A / Q000097:blood*; D014652:Vascular Diseases / Q000175:diagnosis / Q000209:etiology*
D015415:Biomarkers; D010741:Phospholipases A; D054501:Group II Phospholipases A2